The
following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for
the periods presented because including them would have been antidilutive:
Schedule
of Outstanding Shares of Potentially Dilutive Securities
| | |
December 31, | | |
December 31, | |
| | |
2025 | | |
2024 | |
| Convertible Preferred Stock (as converted to common stock) | |
| - | | |
| 5,950,673 | |
| Common Stock Warrants | |
| 92,211 | | |
| 92,211 | |
| Stock options (1) | |
| 686,880 | | |
| 1,700,058 | |
| SPAC public and private placement warrants (2) (refer note
24) | |
| 13,458,750 | | |
| - | |
| Equity Share warrant (refer note 22) | |
| 2,108,070 | | |
| - | |
| Issuance of warrants pursuant to conversion of convertible note (refer note 10) | |
| 30,000 | | |
| - | |
| Antidilutive securities
excluded from computation of earnings per share, amount | |
| 16,375,911 | | |
| 7,742,942 | |
| (1) | | Includes 6,772
stock options as of December 31, 2024, that were early exercised in exchange for non-recourse promissory notes. (Refer to “Note
14 - Stock-based Compensation “). |
| (2) | | The SPAC public
and private placement warrants were outstanding at CSLM Acquisition Corp. prior to the business combination and were classified as equity
and included in APIC in CSLM’s historical financial statements. The warrants became exercisable for shares of Fusemachines, Inc.
common stock 30 days after the consummation of the business combination and were excluded from diluted net loss per share as their inclusion
would have been antidilutive |
|